Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,272.33 -5.18 (-0.10%) Dow
38,429.46 -256.86 (-0.66%) Nasdaq
16,806.39 +71.38 (+0.43%) Bitcoin USD
69,256.57 +1,193.34 (+1.75%) CMC Crypto 200
1,488.73 +20.80 (+1.42%)
BHVN Jul 2024 45.000 put
| Previous close | 9.98 |
| Open | 9.98 |
| Bid | 9.20 |
| Ask | 11.50 |
| Strike | 45.00 |
| Expiry date | 2024-07-19 |
| Day's range | 9.98 - 9.98 |
| Contract range | N/A |
| Volume | |
| Open interest | 8 |
PR NewswireBiohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies, provides an overview of its development and regulatory advances across multiple therapeutic areas, and highlights the progress of its innovative degrader pipeline at the Company's 2024 Investor R&D Day today, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. Members of Biohaven's
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g
GuruFocus.comDirector Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)
On May 13, 2024, Gregory Bailey, Director of Biohaven Ltd (NYSE:BHVN), purchased 15,000 shares of the company.
